Rapporteurs: Victoria Weisfeld, Rebecca A. English, and Anne B. Claiborne
This study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 TO No. 158 and HHSF223001003T), American Society for Microbiology; Amgen Inc.; Association of American Medical Colleges; Bristol-Myers Squibb; Burroughs Wellcome Fund; Celtic Therapeutics, LLLP; Critical Path Institute; Doris Duke Charitable Foundation; Eli Lilly and Co.; FasterCures; Foundation for the NIH; Friends of Cancer Research; GlaxoSmithKline; Johnson & Johnson; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
IOM (Institute of Medicine). 2012. Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary. Washington, DC: The National Academies Press.
Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project.
NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.